Status:
RECRUITING
Head-to-head Study of 68Ga-MGS5 Versus 68Ga-DOTATATE PET/CT in Patients With Medullary Thyroid Carcinoma
Lead Sponsor:
First Affiliated Hospital of Fujian Medical University
Conditions:
Medullary Thyroid Carcinoma
Eligibility:
All Genders
18-80 years
Phase:
PHASE1
Brief Summary
Cholecystokinin-2 (CCK2) receptor is overexpressed in more than 90% of MTC cases, and preclinical studies have shown that 68Ga-MGS5 (targeting CCK2) has good stability in vivo and is promising for dia...
Detailed Description
This study was planned to enroll 20 patients with suspected MTC and MTC recurrence who attended the First Hospital of Fujian Medical University from June 2023 onwards. Each patient completed PET/CT ex...
Eligibility Criteria
Inclusion
- Patients of either gender, aged ≥ 18 years and ≤80 years.
- Patients with pathologic findings confirming the diagnosis of MTC
- Patients with MTC recurrence
- Signed written consent
Exclusion
- Pregnant or breastfeeding female patients
- Patients with claustrophobic behavior
- The inability or unwillingness of the research participant, parent or legal representative to provide written informed consent
Key Trial Info
Start Date :
June 21 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2025
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT06520319
Start Date
June 21 2023
End Date
July 1 2025
Last Update
July 25 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Nuclear Medicine, First Affiliated Hospital of Fujian Medical University
Fuzhou, Fujian, China, 350005